For psoriatic arthritis resistant to other treatments, etanercept may provide better response than the other two frequently used anti–tumor necrosis factor α agents, adalimumab and infliximab.
Etanercept may be expected to provide the greatest American College of Rheumatology (ACR) 20 response among the most frequently used anti–tumor necrosis factor Î± agents (adalimumab, etanercept, and infliximab) compared with placebo in the treatment of patients with psoriatic arthritis (PsA) who are unresponsive to conventional treatments. Migliore and associates at S. Pietro Fatebenefratelli Hospital in Rome performed the first indirect comparison among these biologic agents, in this setting, using a mixed treatment comparison analysis of the data from pivotal trials regarding efficacy profiles of the agents evaluated as ACR 20 response. They noted that their analysis may be relevant for clinical decision making and possibly improving the treatment of patients with PsA. The study appeared in a recent issue of Clinical Rheumatology.